James Shin
Stock Analyst at Deutsche Bank
(2.52)
# 2,967
Out of 5,051 analysts
83
Total ratings
51.4%
Success rate
2.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Shin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Reiterated: Buy | $1,285 | $1,182.62 | +8.66% | 20 | May 7, 2026 | |
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $40 | $15.31 | +161.27% | 1 | Apr 24, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | $51 → $55 | $13.28 | +314.16% | 4 | Mar 25, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $60 | $17.80 | +237.08% | 3 | Mar 9, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $111 → $150 | $145.45 | +3.13% | 9 | Feb 13, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $180 → $204 | $281.12 | n/a | 7 | Sep 15, 2025 | |
| GILD Gilead Sciences | Reiterated: Buy | $120 → $135 | $150.43 | n/a | 5 | Aug 11, 2025 | |
| IMTX Immatics | Initiated Coverage: Buy | $10 | $7.21 | n/a | 1 | May 28, 2025 | |
| IMCR Immunocore Holdings | Initiated Coverage: Buy | $65 | $29.04 | n/a | 1 | May 27, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $45 → $53 | $57.58 | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $305 | $417.57 | n/a | 5 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $60 → $61 | $111.36 | n/a | 5 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €27.00 | €12.21 | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.74 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $880 → $870 | $762.81 | n/a | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $45 | $1.05 | n/a | 2 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $25.33 | n/a | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $14.56 | n/a | 1 | Mar 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.0003 | n/a | 1 | Dec 12, 2022 |
Eli Lilly and Company
May 7, 2026
Reiterated: Buy
Price Target: $1,285
Current: $1,182.62
Upside: +8.66%
Ascentage Pharma Group International
Apr 24, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $15.31
Upside: +161.27%
Sutro Biopharma
Mar 25, 2026
Reiterated: Buy
Price Target: $51 → $55
Current: $13.28
Upside: +314.16%
Legend Biotech
Mar 9, 2026
Reiterated: Buy
Price Target: $60
Current: $17.80
Upside: +237.08%
Merck & Co.
Feb 13, 2026
Upgraded: Buy
Price Target: $111 → $150
Current: $145.45
Upside: +3.13%
AbbVie
Sep 15, 2025
Reiterated: Hold
Price Target: $180 → $204
Current: $281.12
Upside: n/a
Gilead Sciences
Aug 11, 2025
Reiterated: Buy
Price Target: $120 → $135
Current: $150.43
Upside: n/a
Immatics
May 28, 2025
Initiated Coverage: Buy
Price Target: $10
Current: $7.21
Upside: n/a
Immunocore Holdings
May 27, 2025
Initiated Coverage: Buy
Price Target: $65
Current: $29.04
Upside: n/a
Bristol-Myers Squibb Company
Feb 10, 2025
Reiterated: Hold
Price Target: $45 → $53
Current: $57.58
Upside: n/a
Nov 26, 2024
Reiterated: Hold
Price Target: $305
Current: $417.57
Upside: n/a
Sep 19, 2024
Reiterated: Hold
Price Target: $60 → $61
Current: $111.36
Upside: n/a
Aug 12, 2024
Reiterated: Buy
Price Target: €27.00
Current: €12.21
Upside: n/a
Aug 9, 2024
Reiterated: Buy
Price Target: $10
Current: $1.74
Upside: n/a
Aug 1, 2024
Rated: Hold
Price Target: $880 → $870
Current: $762.81
Upside: n/a
Mar 8, 2023
Reiterated: Buy
Price Target: $3 → $45
Current: $1.05
Upside: n/a
Mar 8, 2023
Reiterated: Buy
Price Target: $12
Current: $25.33
Upside: n/a
Mar 5, 2023
Reiterated: Hold
Price Target: $11
Current: $14.56
Upside: n/a
Dec 12, 2022
Reiterated: Buy
Price Target: $7
Current: $0.0003
Upside: n/a